Welch & Forbes LLC Purchases 910 Shares of Eli Lilly and Company $LLY

Welch & Forbes LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 0.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,445 shares of the company’s stock after purchasing an additional 910 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Welch & Forbes LLC’s holdings, making the stock its 18th largest position. Welch & Forbes LLC’s holdings in Eli Lilly and Company were worth $116,497,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $35,000. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. HSBC upped their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $862.96 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $816.76 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The business has a fifty day moving average price of $780.74 and a 200-day moving average price of $771.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.